Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
ALDESLEUKIN (RECOMBINANT INTERLEUKIN-2) - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES, CLINICAL EFFICACY AND TOLERABILITY IN PATIENTS WITH METASTATIC MELANOMA
Autore:
NOBLE S; GOA KL;
Indirizzi:
ADIS INT LTD,41 CENTORIAN DR,PRIVATE BAG 65901 AUCKLAND 10 NEW ZEALAND
Titolo Testata:
Biodrugs
fascicolo: 5, volume: 7, anno: 1997,
pagine: 394 - 422
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACTIVATED KILLER-CELLS; CONTINUOUS-INFUSION INTERLEUKIN-2; ADVANCED MALIGNANT-MELANOMA; HIGH-DOSE INTERLEUKIN-2; STUDY-GROUP TRIAL; INTERCELLULAR-ADHESION MOLECULE-1; PHASE-II; INTERFERON-ALPHA; CANCER-PATIENTS; PERIPHERAL-BLOOD;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
111
Recensione:
Indirizzi per estratti:
Citazione:
S. Noble e K.L. Goa, "ALDESLEUKIN (RECOMBINANT INTERLEUKIN-2) - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES, CLINICAL EFFICACY AND TOLERABILITY IN PATIENTS WITH METASTATIC MELANOMA", Biodrugs, 7(5), 1997, pp. 394-422

Abstract

Aldesleukin [recombinant interleukin-2 (IL-2)] is a biological response modifier which, like endogenous IL-2, has a range of immunomodulatory properties. Although aldesleukin is currently approved only for treatment of renal cell carcinoma, it has been widely used in patients with metastatic melanoma and has been assessed in numerous noncomparative trials in this indication. Durable complete responses have been reported in a small proportion of patients with good performance status who received immunotherapy or chemoimmunotherapy involving aldesleukin in several clinical trials. Overall median survival times of about 10 or 11 months are typical. Combination chemoimmunotherapy involving aldesleukin has produced relatively high response rates (up to 56%), but these are not predictive of increased survival time. Aldesleukin has not been directly compared with standard chemotherapy in randomised studies. The use of continuous intravenous infusion and subcutaneous administration of aldesleukin, together with improved patient selection, has successfully reduced the severity of adverse events produced by the drug (the original intravenous bolus regimen is particularly toxic andoften necessitates admission to an intensive care unit). However; therisk/benefit profile of aldesleukin in the treatment of melanoma requires further study, particularly after subcutaneous administration. Thus, aldesleukin has shown modest efficacy in the treatment of metastatic melanoma. Although aldesleukin-containing regimens have produced promising results in many noncomparative trials, their clinical value incomparison with standard chemotherapy remains to be determined in phase III studies. Until results from such trials are available, clinicians will need to carefully balance the potential benefits of the drug against the risks and likely quality-of-life implications associated with its toxicity in each patient. Current investigations centre on the use of aldesleukin as part of complex biochemotherapy regimens, and results from these trials are awaited with interest.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/10/20 alle ore 23:40:32